Phase 2 Biliary Tract Cancer Clinical Trials
40 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 40 trials
Recruiting
Phase 2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Biliary Tract CancerHepatocellular Carcinoma
AstraZeneca294 enrolled60 locationsNCT05775159
Recruiting
Phase 1Phase 2
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Biliary Tract CancerMelanoma
Hangzhou Hanx Biopharmaceuticals, Ltd.124 enrolled1 locationNCT06708663
Recruiting
Phase 2
Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University40 enrolled1 locationNCT07530445
Recruiting
Phase 1Phase 2
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Biliary Tract Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.102 enrolled43 locationsNCT06431490
Recruiting
Phase 2
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Biliary Tract CancerHepatocellular Carcinoma
Replimune, Inc.60 enrolled12 locationsNCT05733598
Recruiting
Phase 2
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.151 enrolled2 locationsNCT07450976
Recruiting
Phase 2
Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
Biliary Tract CancerUrothelial CarcinomaHER2
Xiujuan Qu20 enrolled1 locationNCT07506057
Recruiting
Phase 1Phase 2
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Biliary Tract Cancer
Akeso135 enrolled1 locationNCT06938321
Recruiting
Phase 2
Ligufalimab and Cadonilimab in Advanced Liver Cancers
Biliary Tract CancerAdvanced Hepatocellular CarcinomaRefractory Hepatocellular Carcinoma
University of Texas Southwestern Medical Center64 enrolled1 locationNCT06789848
Recruiting
Phase 2
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Biliary Tract CancerCholangiocarcinomaGallbladder Cancer+2 more
Case Comprehensive Cancer Center27 enrolled2 locationsNCT07146646
Recruiting
Phase 2
Cosiporfin Sodium for Injection Photodynamic Therapy
Biliary Tract Cancers (BTC)
Shanghai Guangsheng Biopharmaceutical Co., Ltd30 enrolled1 locationNCT07398339
Recruiting
Phase 1Phase 2
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Metastatic Biliary Tract Cancer
M.D. Anderson Cancer Center50 enrolled1 locationNCT06548412
Recruiting
Phase 1Phase 2
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+13 more
Tanabe Pharma America, Inc.27 enrolled6 locationsNCT06943521
Recruiting
Phase 2
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Biliary Tract Cancer
Peking Union Medical College Hospital300 enrolled1 locationNCT07282262
Recruiting
Phase 2
Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer
Biliary Tract Cancer
Peking Union Medical College Hospital45 enrolled1 locationNCT07267078
Recruiting
Phase 2
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Biliary Tract Cancer
UNICANCER72 enrolled3 locationsNCT06529718
Recruiting
Phase 1Phase 2
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Pancreatic Ductal AdenocarcinomaBiliary Tract Cancer (BTC)Gastric or Gastroesophageal Junction Adenocarcinoma
Phanes Therapeutics258 enrolled11 locationsNCT05482893
Recruiting
Phase 2
Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer
Biliary Tract Cancer (BTC)
Peking Union Medical College Hospital100 enrolled1 locationNCT07159204
Recruiting
Phase 2
A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer
Biliary Tract CancerBiliary Tract Cancer (CCA)
Yongjun Chen37 enrolled1 locationNCT07135544
Recruiting
Phase 2
Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer
Biliary Tract CancerHER2HER2 Gene Mutation
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest24 enrolled7 locationsNCT06178445